|Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …|
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
|TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells|
S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ...
Nature 554 (7693), 544-548, 2018
|Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma|
DF McDermott, MA Huseni, MB Atkins, RJ Motzer, BI Rini, B Escudier, ...
Nature medicine 24 (6), 749-757, 2018
|Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients|
A Palanichamy, S Jahn, D Nickles, M Derstine, A Abounasr, SL Hauser, ...
The Journal of Immunology 193 (2), 580-586, 2014
|A PP4 holoenzyme balances physiological and oncogenic nuclear factor-kappa B signaling in T lymphocytes|
M Brechmann, T Mock, D Nickles, M Kiessling, N Weit, R Breuer, W Müller, ...
Immunity 37 (4), 697-708, 2012
|Genetics of multiple sclerosis: swimming in an ocean of data|
SE Baranzini, D Nickles
Current opinion in neurology 25 (3), 239-245, 2012
|Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls|
D Nickles, HP Chen, MM Li, P Khankhanian, L Madireddy, SJ Caillier, ...
Human molecular genetics 22 (20), 4194-4205, 2013
|An RNAi screen identifies USP2 as a factor required for TNF‐α‐induced NF‐κB signaling|
M Metzig, D Nickles, C Falschlehner, J Lehmann‐Koch, BK Straub, ...
International journal of cancer 129 (3), 607-618, 2011
|Anti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment|
H Xiong, S Mittman, R Rodriguez, M Moskalenko, P Pacheco-Sanchez, ...
Cancer research 79 (7), 1493-1506, 2019
|The autoimmune disease-associated transcription factors EOMES and TBX21 are dysregulated in multiple sclerosis and define a molecular subtype of disease|
GP Parnell, PN Gatt, M Krupa, D Nickles, FC McKay, SD Schibeci, ...
Clinical immunology 151 (1), 16-24, 2014
|PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC …|
JE Rosenberg, DP Petrylak, MS Van Der Heijden, A Necchi, ...
Journal of Clinical Oncology 34 (15_suppl), 104-104, 2016
|Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.|
FA Legrand, DR Gandara, S Mariathasan, T Powles, X He, W Zhang, ...
Journal of Clinical Oncology 36 (15_suppl), 12000-12000, 2018
|A genome-wide RNA interference screen identifies caspase 4 as a factor required for tumor necrosis factor alpha signaling|
D Nickles, C Falschlehner, M Metzig, M Boutros
Molecular and cellular biology 32 (17), 3372-3381, 2012
|In depth comparison of an individual’s DNA and its lymphoblastoid cell line using whole genome sequencing|
D Nickles, L Madireddy, S Yang, P Khankhanian, S Lincoln, SL Hauser, ...
BMC genomics 13 (1), 1-11, 2012
|Sequencing of the IL6 gene in a case–control study of cerebral palsy in children|
P Khankhanian, SE Baranzini, BA Johnson, L Madireddy, D Nickles, ...
BMC medical genetics 14 (1), 1-8, 2013
|The autoimmune risk gene ZMIZ1 is a vitamin D responsive marker of a molecular phenotype of multiple sclerosis|
NL Fewings, PN Gatt, FC McKay, GP Parnell, SD Schibeci, J Edwards, ...
Journal of autoimmunity 78, 57-69, 2017
|Coexpression of inhibitory receptors enriches for activated and functional CD8+ T cells in murine syngeneic tumor models|
H Xiong, S Mittman, R Rodriguez, P Pacheco-Sanchez, M Moskalenko, ...
Cancer immunology research 7 (6), 963-976, 2019
|Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)|
T Powles, D Nickles, E Van Allen, C Chappey, W Zou, M Kowanetz, ...
Journal for ImmunoTherapy of Cancer 3 (2), 1-2, 2015
|End-stage dying glioma cells are engulfed by mouse microglia with a strain-dependent efficacy|
D Nickles, A Abschuetz, H Zimmer, T Kees, R Geibig, E Spiess, ...
Journal of neuroimmunology 197 (1), 10-20, 2008
|NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes|
A Singh, A Daemen, D Nickles, SM Jeon, O Foreman, K Sudini, F Gnad, ...
Clinical Cancer Research 27 (3), 877-888, 2021